Y-mAbs Therapeutics (NASDAQ:YMAB) Trading 5.6% Higher

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) shares traded up 5.6% during mid-day trading on Monday . The stock traded as high as $14.51 and last traded at $14.51. 277,116 shares changed hands during mid-day trading, a decline of 22% from the average session volume of 355,238 shares. The stock had previously closed at $13.74.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. BMO Capital Markets cut their price objective on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. Wedbush reiterated an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, August 12th. Truist Financial assumed coverage on Y-mAbs Therapeutics in a research report on Friday, June 28th. They issued a “buy” rating and a $21.00 price objective for the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $26.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Finally, Cantor Fitzgerald started coverage on Y-mAbs Therapeutics in a research note on Friday, August 16th. They issued an “overweight” rating and a $20.00 target price for the company. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $21.14.

Y-mAbs Therapeutics Price Performance

The business has a 50 day moving average of $12.19 and a 200 day moving average of $13.75. The firm has a market capitalization of $685.93 million, a price-to-earnings ratio of -31.41 and a beta of 0.66.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Monday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The business had revenue of $22.80 million during the quarter, compared to analyst estimates of $23.09 million. During the same period in the previous year, the firm posted ($0.14) earnings per share. As a group, equities analysts predict that Y-mAbs Therapeutics, Inc. will post -0.57 EPS for the current year.

Insider Activity

In other news, CFO Bo Kruse sold 31,371 shares of the business’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $12.07, for a total value of $378,647.97. Following the sale, the chief financial officer now directly owns 210,877 shares in the company, valued at $2,545,285.39. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, COO Joris Wilms sold 5,000 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the sale, the chief operating officer now owns 30,600 shares in the company, valued at $449,514. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Bo Kruse sold 31,371 shares of the company’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $12.07, for a total value of $378,647.97. Following the sale, the chief financial officer now owns 210,877 shares in the company, valued at approximately $2,545,285.39. The disclosure for this sale can be found here. Insiders have sold a total of 72,093 shares of company stock worth $881,812 over the last three months. Corporate insiders own 21.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Campbell & CO Investment Adviser LLC acquired a new position in Y-mAbs Therapeutics during the fourth quarter worth approximately $562,000. Federated Hermes Inc. increased its position in Y-mAbs Therapeutics by 4,708.0% during the fourth quarter. Federated Hermes Inc. now owns 44,474 shares of the company’s stock worth $303,000 after buying an additional 43,549 shares during the last quarter. Sapient Capital LLC acquired a new position in Y-mAbs Therapeutics during the fourth quarter worth approximately $298,000. Bailard Inc. acquired a new position in Y-mAbs Therapeutics during the fourth quarter worth approximately $115,000. Finally, Ameritas Investment Partners Inc. increased its position in Y-mAbs Therapeutics by 39.9% during the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock worth $60,000 after buying an additional 1,056 shares during the last quarter. Institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.